Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| LPCN | Lipocine | $2.05 | -$7.20 | -77.84% | 7M | $68M | $1.81$12.37 |
| ELAB | Pmgc | $5.72 | -$8.28 | -59.14% | 24.7M | $7.6M | $1.62$466.20 |
| SST | System1 | $3.57 | -$1.65 | -31.61% | 2.7M | $42M | $1.35$15.00 |
| EEIQ | EpicQuest Education Group International | $7.25 | -$3.33 | -31.47% | 660.9K | $16M | $1.90$27.84 |
| RENX | RenX Enterprises | $2.02 | -$0.59 | -22.61% | 1.5M | $6.1M | $1.42$47.20 |
| CDT | Cdt Equity | $3.95 | -$1.15 | -22.55% | 146.7K | $902K | $3.83$4,200.00 |
| FGI | Fgi Industries | $3.85 | -$1.12 | -22.54% | 69K | $9.5M | $2.28$12.62 |
| JFU | 9f | $2.97 | -$0.52 | -14.90% | 34.2K | $30M | $1.01$9.48 |
| ANGO | AngioDynamics | $10.31 | -$1.63 | -13.65% | 1.2M | $492M | $8.36$13.99 |
| UGRO | Urban-gro | $19.00 | -$2.98 | -13.56% | 925.6K | $17M | $2.02$37.00 |
| ADAG | Adagene | $3.99 | -$0.62 | -13.45% | 1.2M | $217M | $1.30$4.72 |
| WCT | Wellchange | $2.61 | -$0.38 | -12.76% | 7.8K | $8.7M | $1.46$25.00 |
| FTLF | FitLife Brands | $10.61 | -$1.49 | -12.31% | 51.6K | $114M | $9.83$20.98 |
| MNTS | Momentus | $3.28 | -$0.45 | -12.06% | 1.7M | $5.2M | $3.16$43.55 |
| LNN | Lindsay | $103.02 | -$14.13 | -12.06% | 364.4K | $1.2B | $102.87$150.96 |
| SOLT | Volatility Shares Trust - 2x Solana ETF | $41.16 | -$5.49 | -11.77% | 649.8K | - | $38.62$706.00 |
| EKSO | Ekso Bionics | $9.40 | -$1.25 | -11.74% | 209.1K | $38M | $2.73$13.50 |
| LVLU | Lulu's Fashion Lounge | $11.33 | -$1.34 | -10.54% | 15.6K | $35M | $2.98$32.32 |
Related Articles
Featured Article
Should Growth Investors Buy This Revolutionary Small-Cap Stock?
Kody Kester|Jul 25, 2023
The medical devices company is taking an exciting approach to treating some of the most complex diseases.
Wall Street Thinks This Small-Cap Stock Can Double in Value
Kody Kester|Apr 4, 2023
Analysts are projecting a huge rebound from this beaten-down stock in the next 12 months.
Is This Under-the-Radar Growth Stock a Buy?
Kody Kester|Jan 19, 2023
This company is a small player in the steadily growing medtech industry.
Wall Street Thinks This Obscure Growth Stock Could Soar 92% in 2023
Kody Kester|Dec 30, 2022
As COVID-19 headwinds fade, AngioDynamics' business could rebound.
Here's Why This Hidden Growth Stock Is a Buy
Kody Kester|Oct 21, 2022
This medical device company may not be a household name, but it could be an up-and-comer.
Should You Buy This Under-the-Radar Growth Stock?
Kody Kester|Jul 29, 2022
Like the Nasdaq Composite, this little-known medical device stock has been beaten down in 2022.
3 Reasons to Consider Buying This Overlooked Medical Device Stock
Kody Kester|May 1, 2022
The Nasdaq's sell-off looks to have given investors a buying opportunity in this little-known medical device stock.
Is This Small-Cap Medical Devices Stock a Buy?
Kody Kester|Feb 1, 2022
AngioDynamics managed to deliver solid revenue growth in the second quarter despite COVID-19 headwinds.
Is This Under-the-Radar Medical Devices Stock a Buy?
Kody Kester|Nov 3, 2021
The medical devices company beat analyst expectations in the first quarter of its new fiscal year. Could it be a buy?
After Beating Estimates, Is This Little-Known Medical Device Company a Buy?
Kody Kester|Jul 18, 2021
AngioDynamics exceeded analyst expectations on revenue in Q4 2021, but does that make it worth buying?
